indazoles has been researched along with Adenocarcinoma in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.11) | 18.7374 |
| 1990's | 10 (27.03) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 12 (32.43) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A | 1 |
| Baltes, F; Bendas, G; Caspers, J; Henze, S; Schlesinger, M | 1 |
| Dueñas-Gonzalez, A; Schcolnik-Cabrera, A | 1 |
| Du, X; Hu, D; Jiang, L; Luo, S; Tang, W; Tang, Y; Zhao, G; Zhao, X | 1 |
| Dang, KX; Haglund, C; Ho, TH; Koistinen, H; Lintula, S; Mustonen, H; Räsänen, K; Stenman, J; Stenman, UH | 1 |
| Bajpai, P; Gupta, VG; Rangaraju, RR; Saha, R | 1 |
| Alessi, DR; Arbeiter, A; Baccarini, M; Dobler, M; Eser, S; Esposito, I; Gottschalk, K; Hieber, M; Kind, AJ; Klein, S; Kong, B; Messer, M; Michalski, CW; Rad, L; Rad, R; Reiff, N; Saur, D; Schlitter, AM; Schmid, RM; Schneider, G; Schnieke, AE; Seidler, B | 1 |
| Calogero, A; Ciccone, AM; De Falco, E; Ibrahim, M; Menna, C; Pacini, L; Petrozza, V; Puca, R; Rendina, EA; Ruggieri, P; Scafetta, G | 1 |
| Besse, B; Bosquee, L; Chouaid, C; Felip, E; Lechevalier, T; Lianes-Barragán, P; Mellemgaard, A; Ottesen, LH; Paul, EM; Reck, M; Ruiz-Soto, R; Scagliotti, GV; Sigal, E; von Pawel, J | 1 |
| Avril, N; Hagemann, T; Hudson, CD; Mather, SJ | 1 |
| Pattison, S; Zalcberg, JR | 1 |
| Jung, SH; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS | 1 |
| Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC | 1 |
| Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS | 1 |
| Besse, B; Carlson, DM; Gandara, DR; Goss, GD; Gupta, N; Hanna, NH; Hensing, T; Lee, C; Mazieres, J; Pradhan, R; Qian, J; Qin, Q; Ricker, JL; Salgia, R; Scappaticci, FA; Soo, RA; Tan, EH; Thertulien, R; Wertheim, M; Yang, JC | 1 |
| Kraut, E; Moore, T; Philip Kuebler, J; Pritchard, J | 1 |
| Chang, YL; Guh, JH; Huang, YT; Kuo, SC; Lee, FY; Pan, SL; Teng, CM | 1 |
| Bogdanov, A; Hu-Lowe, D; Reichardt, W; Torres, D; Weissleder, R | 1 |
| Bogdanov, AA; Figueiredo, J; Hu-Lowe, D; Kang, HW; Kim, YR; Mahmood, U; Petrovsky, A; Reichardt, W; Torres, D; Weissleder, R; Yudina, A | 1 |
| Han, H; Von Hoff, DD; Wang, H | 1 |
| Ashok Kumar, B; Gururaj, S; Lingaiah, BP; Narsaiah, B; Parthasarathy, T; Shireesha, B; Sridhar, B; Yakaiah, T | 1 |
| Fuchs, AG | 1 |
| Biglietto, M; Carteni, G; De Cesare, M; Pacilio, G | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B | 1 |
| Bearzatto, A; Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
| Bloch, WE; Block, NL; Ferrell, SM; Lokeshwar, BL | 1 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Berni, F; Calzavara, MP; Cattaneo, MT; D'Adda, D; Filipazzi, V; Frontini, L; Isa, L; Legnani, W; Rho, B; Scapaticci, R | 1 |
| Mori, K; Suga, Y; Takahashi, T; Tominaga, K | 1 |
| Aldous, S; Corbett, TH; Coughlin, SA; Huang, JI; Jones, JL; Klingbeil, KM; Mattes, KC; Perni, RB; Peverly, AD; Powles, RG; Rake, JB; Robinson, RG; Wentland, MP | 1 |
| Beggiolin, G; Di Domenico, R; Fiocchi, L; Gallagher, CE; Giuliani, FC; Hacker, MP; Krapcho, AP; Maresch, ME; Menta, E; Oliva, A; Pezzoni, G; Spinelli, S | 1 |
| Ferris, AM; LoRusso, PM; Philip, PA; Shields, AF; Zalupski, MM | 1 |
| Abbruzzese, JL; Dakhil, SR; Ellerton, JA; Hoff, PM; Pazdur, R; Winn, RJ | 1 |
| Eble, M; Flentje, M; Hör, A; Latz, D; Wannenmacher, M | 1 |
| Ciottoli, GB; De Gregorio, M; Kokron, O; Maca, S | 1 |
| Basurto, C; Bertusi, M; Bisagni, G; Buzzi, F; Di Costanzo, F; Donati, D; Gori, S; Passalacqua, R | 1 |
2 review(s) available for indazoles and Adenocarcinoma
| Article | Year |
|---|---|
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2016 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
12 trial(s) available for indazoles and Adenocarcinoma
| Article | Year |
|---|---|
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Female; Fluorouracil; Humans; Indazoles; Male; Middle Aged; Oxaliplatin; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2022 |
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrimidines; Sulfonamides; Survival Rate | 2013 |
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Follow-Up Studies; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Pyrimidines; Stomach Neoplasms; Sulfonamides; Young Adult | 2016 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2010 |
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Indazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Indazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms | 2004 |
Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Double-Blind Method; Female; Humans; Indazoles; Male; Middle Aged; Muscles; Pyrazoles; Random Allocation | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Phase II study of CI-958 in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Indazoles; Intercalating Agents; Leukopenia; Male; Middle Aged | 1999 |
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged | 2000 |
Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Italy; Male; Middle Aged; Neoplasm Metastasis; Pyrazoles | 1989 |
24 other study(ies) available for indazoles and Adenocarcinoma
| Article | Year |
|---|---|
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Discoidin Domain Receptor 1; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indazoles; Integrin beta1; Integrin beta4; MAP Kinase Signaling System; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Piperazines; Tumor Microenvironment | 2020 |
Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Diazooxonorleucine; Drug Screening Assays, Antitumor; Fatty Acid Synthase, Type I; Fatty Acids; Female; Glutaminase; Glutamine; Glycolysis; Hexokinase; Indazoles; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Orlistat; Smegmamorpha | 2021 |
NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atlases as Topic; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Piperidines; Prostatic Neoplasms, Castration-Resistant; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2021 |
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Topics: Activating Transcription Factor 4; Adenocarcinoma; Aged; Caco-2 Cells; Cell Line, Tumor; Cohort Studies; Colorectal Neoplasms; Female; HT29 Cells; Humans; Indazoles; Male; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Trypsin Inhibitor, Kazal Pancreatic | 2018 |
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged, 80 and over; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Fatal Outcome; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Stomach; Stomach Neoplasms; Sulfonamides; Treatment Outcome | 2019 |
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; Humans; Indazoles; Lithostathine; Metaplasia; Mice; Mice, Inbred NOD; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Signal Transduction; Sulfonamides; TNF Receptor-Associated Factor 3; Transplantation, Heterologous; Tumor Cells, Cultured | 2013 |
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Axitinib; Cell Movement; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Radiography; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Axitinib; Cell Membrane; Cell Proliferation; Cell Shape; Cell Survival; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Glucose; Glucose Transporter Type 1; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indazoles; Mice; Mitosis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2014 |
Bespoke treatment: drivers beware!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Microtubule-Associated Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Oncogenes; Pancreatic Neoplasms; Paraneoplastic Syndromes; Pyrimidines; Radiography; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides | 2014 |
YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Male; Mice; Mice, SCID; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Prostatic Neoplasms; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2005 |
Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood Volume; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Ferric Compounds; Humans; Indazoles; Magnetic Resonance Imaging; Mice; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Colonic Neoplasms; Erythrocyte Volume; Humans; Indazoles; Magnetic Resonance Angiography; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Radionuclide Imaging; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Drug Screening Assays, Antitumor; Feasibility Studies; Fibroblasts; G2 Phase; Gene Expression Profiling; Humans; Indazoles; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; S Phase; Smad4 Protein | 2006 |
Synthesis and structure-activity relationships of novel pyrimido[1,2-b]indazoles as potential anticancer agents against A-549 cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Quantitative Structure-Activity Relationship; Tubulin | 2007 |
[Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Hexokinase; HT29 Cells; Humans; Indazoles; Mitochondria | 2008 |
In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indazoles; Mitomycin; Tumor Cells, Cultured | 1994 |
Enhancement of hyperthermic toxicity by lonidamine in the Dunning R3327G rat prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Hot Temperature; Hyperthermia, Induced; Indazoles; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1994 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged | 1993 |
[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
Topics: Adenocarcinoma; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granisetron; Humans; Indazoles; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Nausea; Vindesine; Vomiting | 1993 |
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Intercalating Agents; Leukemia P388; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Pyrans; Structure-Activity Relationship; Thioxanthenes; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1998 |
Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Indazoles; Inhibitory Concentration 50; Isoquinolines; Leukemia P388; Male; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Tumor Cells, Cultured | 1998 |
[Effects of lonidamine alone or in combination with radiotherapy on survival and metabolism in human and rodent cell lines].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Humans; Hydrogen-Ion Concentration; Indazoles; Lung Neoplasms; Mice; Mitochondria; Oxidoreductases; Radiotherapy Dosage; Tetrazolium Salts; Tumor Cells, Cultured | 1991 |
Phase II study of lonidamine in non-small cell lung cancer: final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles | 1990 |